by Orphagen Pharma | Jan 17, 2023 | News, Uncategorized
SAN DIEGO–(BUSINESS WIRE)–Orphagen Pharmaceuticals, Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced that the...
by goldfishadmin | Jun 11, 2022 | News
SAN DIEGO, June 11, 2022 – Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from...
by Orphagen Pharma | Apr 8, 2022 | News
SAN DIEGO, April 8, 2022 — Orphagen Pharmaceuticals Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced a late-breaking...
by Orphagen Pharma | Oct 18, 2021 | News
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Cancer Institute (NCI) has indicated its intention to award the company $2.0 million under the Small Business Innovation Research (SBIR) program to support preclinical...
by Orphagen Pharma | Oct 15, 2021 | News
Orphagen Pharmaceuticals, a preclinical stage biopharmaceutical company focused on discovering and developing first-in-class therapeutics for cancer and inflammatory disease, announced the promotion of Paul Crowe to Vice President, Drug Discovery, effective June 30,...
by Orphagen Pharma | May 5, 2021 | News
Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that data from its preclinical program to develop OR-449 for...
